GP 668

Drug Profile

GP 668

Alternative Names: GP 1668

Latest Information Update: 26 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SICOR
  • Class Anti-ischaemics; Antiarrhythmics; Antithrombotics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 26 Nov 2007 Discontinued - Phase-I for Ischaemic heart disorders in USA (unspecified route)
  • 26 Nov 2007 Discontinued - Phase-I for Myocardial infarction in USA (unspecified route)
  • 26 Nov 2007 Discontinued - Phase-I for Unstable angina pectoris in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top